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Endometrial cancer is the seventh most common cancer in women worldwide. Therefore elucidation of the pathogenesis
and development of eﬀective treatment for endometrial cancer are important. However, several aspects of the mechanism of
carcinogenesis in the endometrium remain unclear. Associations with genetic variation and mutations of cancer-related genes
have been shown, but these do not provide a complete explanation. Therefore, in recent years, epigenetic mechanisms that do not
involve changes in DNA sequences have been examined. Studies aimed at detection of aberrant DNA hypermethylation in cancer
cells present in microscopic amounts in vivo and application of the results to cancer diagnosis have also started. Breakdown of
the DNA mismatch repair mechanism is thought to play a large role in the development of endometrial cancer, with changes in
the expression of the hMLH1 gene being particularly important. Silencing of genes such as APC and CHFR, Sprouty 2, RASSF1A,
GPR54, CDH1,a n dRSK4 by DNA hypermethylation, onset of Lynch syndrome due to hereditary epimutation of hMLH1 and
hMSH2 mismatch repair genes, and regulation of gene expression by microRNAs may also underlie the carcinogenic mechanisms
of endometrial cancer. Further understanding of these issues may permit development of new therapies.
1.Introduction
Endometrial cancer is the seventh most common cancer
in women worldwide. In Japan, westernization of lifestyle
has increased the number of patients with endometrial
cancer, and this disease now accounts for about 40% of
cancers of the uterus. A further increase, and a younger
onset age are also predicted, and therefore elucidation of
the pathogenesis and development of eﬀective treatment are
needed. However, the mechanism of carcinogenesis in the
endometrium remains unclear. Genetic aberrances such as
variations in gene expression and mutation of cancer-related
genes have been identiﬁed, but these do not fully explain
canceration in the endometrium. Therefore, epigenetic
changes in gene expression through eﬀects on chromatin
without DNA mutation are drawing attention. Breakdown
of the DNA mismatch repair mechanism by aberrant DNA
hypermethylation is particularly important for development
of type 1 endometrial cancer, and changes in expression
of genes such as human MutL homolog1 (hMLH1)a n d
human MutS homolog2 (hMSH2) may be involved in this
mechanism. The possible epigenetic mechanisms include
epimutation, hypermethylation causing epimutation, and
regulation of gene expression by small noncoding RNAs,
calledmicroRNAs,thatbindupstreamofthegeneanddonot
change the methylation level of the gene itself. In this review,
DNA hypermethylation associated with endometrial cancer
based on epimutation of three genes, hMLH1, hMSH2 and
epithelial cell adhesion molecule (EPCAM), and the eﬀects
of miRNAs in endometrial cancer will be discussed.
2. New Findingson DNA Hypermethylation
inEndometrialCancer
Among the epigenetic mechanisms, DNA methylation has
beenmostwidelystudied.ChangesinDNAmethylationhave
been associated with various tumorous lesions [1, 2], and
hypermethylation is commonly associated with downregula-
tion of gene expression. Our review in 2009 [3]p r o m p t e d2 Biochemistry Research International
further studies of aberrant DNA hypermethylation associ-
ated with endometrial cancer, and it has been found that
hypermethylation of gene promoters is linked to reduced
expression of several genes in this cancer. We have reported
silencing due to hypermethylation for hMLH1 and adeno-
matous polyposis coli (APC), E-cadherin, checkpoint with
FHA and RING (CHFR), caspase-8 (CASP8), transforming
growth factor, beta receptor II (TGF-bRII), p73,h o m e o b o x
A11 (HOXA11), and catechol-O-methyltransferase (COMT)
[3], and genes such as Sprouty 2 [4], Ras association domain
family 1 isoform A (RASSF1A)[ 5], G-protein coupled
receptor 54 (GPR54)[ 6], cadherin 1 (CDH1)[ 7], and
ribosomal S6 kinase4 (RSK4)[ 8] have also been found to
be silenced by a similar mechanism. Hypermethylation of
the APC promoter is not found in the normal endometrium
or in endometrial hyperplasia but is detected in atypical
hyperplasia and early endometrial cancer. Interestingly, the
frequency of hypermethylation in the APC promoter is
reduced with progression of endometrial cancer, which led
Ignatov et al. to suggest that this hypermethylation may be
an important event in early canceration of the endometrium
[9]. Satoh et al. linked hypermethylation to the response of
tumors to taxane drugs [10], and Wang et al. found that
reduced expression of CHFR by hypermethylation improves
the response of both stomach and endometrial cancers
to paclitaxel [11]. These studies suggest the possibility
of personalized cancer treatment adapted to each patient
following examination of the expression levels of multiple
genes.
Sprouty 2 (SPRY2) is an antagonist regulator of receptor
tyrosine kinases in the ﬁbroblast growth factor (FGF) and
RAS-MAPK pathways and a tumor suppressor gene involved
in cell proliferation, diﬀerentiation, and angiogenesis. Parts
of the FGF and RAS-MAPK pathways are changed in
endometrial cancer, and expression of SPRY2 is reduced
due to hypermethylation in several types of cancer [12–14].
Velasco et al. found that SPRY2 in the normal endometrium
is expressedin accordwiththemenstrualcycleandsuggested
that SPRY2 contributes to growth of glandular structures
[4]. SPRY2 expression is extremely low in advanced invasive
cancers and other types of endometrial cancer, other than
endometrioid adenocarcinoma, which indicates that SPRY2
may play a role in suppression of endometrial cancer by
regulating the MAPK pathway [4].
RASSF1A is a tumor suppressor that is a negative reg-
ulator in the RAS-MAPK pathway and, along with SPRY2,
has reduced expression in various cancers. In a compari-
son of normal and cancerous endometrial tissues, Pallares
et al. showed that RASSF1A promoter hypermethylation
and reduced expression were particularly prevalent in
endometrial cancer with microsatellite instability, especially
in advanced cancers [5]. This led to the suggestion that
RASSF1A participates in cell proliferation and apoptosis by
regulating the MAPK pathway and has eﬀects on canceration
of the endometrium [5].
GPR54 is a gene-encoding endogenous receptor of
kisspeptin (KISS1), a suppressor of cancer metastasis, and has
reduced expression in some cancers, but an unclear status
in endometrial cancer. Kang et al. found high survival
rates in cases with high GPR54 expression and showed
that expression of GPR54 is epigenetically regulated [6].
Functional recovery of GPR54 was possible with treatment
with 5-aza-dC, a drug that causes DNA hypomethylation,
and subsequent expression of GPR54 and activation of a
downstream response pathway involving metastin-10 were
eﬀective for inhibiting metastasis of endometrial cancer [6].
CDH1 is a promoter of E-cadherin. Yi et al. found that
hypermethylation of CDH1 reduced E-cadherin expression
in endometrial cancer, with resulting eﬀects on clinical
and pathological progression and 5-year survival rates.
Hypermethylation of CDH1 is common in undiﬀerentiated
cancers, leading to the suggestion that this mechanism may
be closely associated with canceration and invasive capacity
[7].
X-linked Ribosomal S6 Kinase RPS6KA6 (RSK4)i sas u b -
strate of ERK that inhibits transcriptional activity of some
receptor tyrosine kinases for certain targets. RSK4 is also
associated with the FGFR2/RAS/ERK signal pathway and is
a tumor suppressor. Dewdney et al. showed that expression
ofRSK4isreducedbyhypermethylationincolon,breast,and
kidneycancer,aswellasinendometrialcancer,butthetumor
inhibitory action of RSK4 in the endometrium is unclear [8].
3. EpimutationandCarcinogenesis
of the Endometrium
Epimutation refers to the epigenetic silencing of a gene
for which expression is normally not suppressed, or epi-
genetic activation of a gene for which expression is nor-
mally suppressed [15, 16]. Studies of canceration of the
endometrium and epimutation of genes have mainly focused
on hMLH1, hMSH2,a n dEPCAM. hMLH1 and hMSH2 are
DNA mismatch repair (MMR) genes that have a strong
association with endometrial cancer, above that of other
MMR genes such as hMSH6 and PMS2 [17]. Kondo et al.
ﬁrst showed that epigenetic inhibition of hMLH1 expression
is more frequent than that of hMSH2 in endometrial cancer
[18]. Most subsequent studies have examined hMLH1, and
this gene has been found to be a tumor suppressor that
has reduced expression in various cancers. Mutation of
hMLH1 is especially common in cases with multiple primary
cancers such as, for example, in Lynch syndrome (hereditary
nonpolyposis colorectal cancer: HNPCC), and epimutation
of the germline may be present even if mutation of hMLH1
itself does not occur [19]. Hitchins et al. suggested that
the epimutation may be inherited through the mother since
during egg formation an epigenetic error can essentially
be solved by demethylation; however, this type of heredity
epimutation occurs with lower frequency than the germline
mutation [20]. However, in one of two cases in which
epimutation of hMLH1 occurred de novo, Goel et al. showed
that the epimutation occurred in the allele derived from
the father, rather than the mother [21]. This defect may
have occurred during egg formation without demethylation,
and the epimutation may have been inherited or may have
occurred as a new epimutation after fertilization.Biochemistry Research International 3
An inherited germline epimutation of hMSH2 was
reported in 2006 by Chan et al. [22] in a family line of three
patients (brothers and sisters) with colon or endometrial
cancer with onset at an early age. Genetic mutation of
hMSH2 was not present, but protein deﬁciency was rec-
ognized, and microsatellite instability was shown, with the
epimutation of hMSH2 inherited from the mother. The same
epimutation was inherited by three children of the three
patients, indicating that not only a DNA sequence mutation
but also an epimutation can be inherited over multiple
generations. Sequencing shows that the epimutation does
not occur in all cells and methylation mosaics exist. Diﬀerent
degrees of methylation occur based on the two-hit theory
and can be the cause of heritability of diseases.
The EPCAM gene codes for an epithelial cell adhesion
molecule and is overexpressed in most cancers. There is a
diversity of opinion on the eﬀects of EPCAM on canceration.
EPCAM is a homophilic intercellular adhesion molecule
that may prevent metastasis, but conversely EPCAM may
also promote metastasis of cancers to prevent intercellular
adhesion mediated by E-cadherin [23]. In endometrial can-
cer, EPCAM deﬁciency is also involved in hypermethylation
of the hMSH2 promoter [24]. Ligtenberg et al. found that
epimutation of EPCAM itself is not involved in development
of endometrial cancer, but a mutation to the 3 side of
EPCAM upstreamandclosetohMSH2epigeneticallysilences
hMSH2 and may lead to endometrial cancer and Lynch
syndrome.
4. Endometrial CancerandRegulation with
AberrantMethylation of MicroRNA
MicroRNAs (miRNAs) are short noncoding RNAs of about
18–25 bases that regulate expression of genes. miRNAs have
been found to be downregulated by methylation of DNA in
various cancers, and these miRNAs are referred to as tumor
suppressor miRNAs (TS-miRNAs) [25, 26]. Identiﬁed TS-
miRNAs include miR-124, miR-126, miR-137,a n dmiR-491
[25–29]. Using a microarray assay, Huang et al. found that
SRY-related high-mobility group box 4 (SOX4) genes were
highly expressed in endometrial cancer cells. In database
analysis, SOX4 was identiﬁed as a target for miR-129-2,
and a reporter assay showed that miR-129-2 was a negative
regulator of SOX4. Expression of miR-129-2 was veriﬁed in
117 cases of endometrial cancer with increased expression
of SOX4, and in 68% of the patients SOX4 expression
was silenced by methylation. Histone acetylation and DNA
demethylation were found to increase the expression of miR-
129-2,r e d u c eSOX4 expression, and suppress proliferation of
cancer cells. Furthermore, hypermethylation of the miR-129-
2genewasstatisticallyrelatedtomicrosatelliteinstabilityand
the methylation status of hMLH1 [30].
Expression of miR-152 is also inhibited by DNA hyper-
methylation [31]. Tsuruta et al. identiﬁed miR-152 as
a candidate TS-miRNA in endometrial cancer through
DNA methylation screening and expression screening of
endometrial cancer cells. Methylation of miR-152 is altered
in acute lymphocytic leukemia, and miR-152 expression
is changed in digestive system cancers and cholangiocel-
l u l a rc a n c e r[ 32–34]. Tsuruta et al. found methylation
and downregulation of miR-152 at high frequency and
showed that expression of miR-152 is recovered by 5-aza-
dC. Methylation of miR-152 is completely consistent with
expression, and hypermethylation in the promoter region of
miR-152 reduces the expression. DNMT1 is a well-known
target of miR-152,a n dE2F3, MET, and Rictor have been
identiﬁed as additional targets [34]. E2F3 is an E2F family
transcriptional inhibitor and may be a cancer gene [35].
MET is a gene that encodes a cell-surface receptor for
hepatocyte growth factor and a known cancer gene [36].
Rictor is a component of mTORC2 (mTOR complex 2)w h i c h
directly regulates phosphorylation of Akt and is important
in cancer cells [37, 38]. Activation of mTORC2-Akt signaling
contributes to canceration of the endometrium, but the
action of Rictor in canceration is unclear. However, silenc-
ing of miR-152 appears to lead to activation of multiple
targets, and miR-152 itself and E2F3, MET, and Rictor
m a yb en e wt a r g e t sf o rt r e a t m e n to fe n d o m e t r i a lc a n c e r
[31].
5. Conclusion
In 2007, endometrial cancer was newly diagnosed in as many
as 226,000 women worldwide and is the cause of death of
more than 7000 people annually in the USA alone. In Japan,
the number of patients with this cancer is increasing and
a younger age of onset is also predicted, which emphasizes
the need to ﬁnd more eﬀective therapies based on improved
understanding of the pathogenesis. As for many other
cancers, development of endometrial cancer cannot be com-
pletely explained by genetic mutations alone and is likely to
involveepigeneticchanges.Inendometrialcancer,mutations
of MMR genes are important, and regulation of these genes
has been widely examined. Expression of hMLH1, hMSH2,
and EPCAM is suppressed by promoter hypermethylation,
which inhibits direct or indirect DNA mismatch repair and
contributes to development of endometrial cancer type 1
and development of endometrial cancer in Lynch syndrome.
Reduced expression of genes such as APC, CHFR, Sprouty 2,
RASSF1A,GPR54,CDH1,andRSK4throughasimilarmech-
anism of hypermethylation has also been found in endome-
trial cancer. Suppression of gene expression by miRNAs also
occurs in endometrial cancer, and expression of the miRNA
itself may be increased or decreased by promoter methyla-
tion, based on diﬀerences between normal and cancerous
endometrial tissue, and may contribute to canceration of the
endometrium.
The studies described above have contributed to grad-
ual elucidation of the mechanisms of canceration in the
endometrium, but the ﬁndings do not seem to be applicable
to all cases. Thus, it is unclear whether there is a common
underlying mechanism or whether the apparently similar
pathological conditions among cases of endometrial cancer
are actually somewhat diﬀerent and new classiﬁcations are
needed. More knowledge of the canceration mechanism
should reveal new therapeutic targets and discovery of new4 Biochemistry Research International
drugs. This is especially true for miRNA targeting since
siRNA modulation of miRNA has been established in vitro
and a similar approach in vivo may prevent progression of
cancerationcausedbysilencingofmiRNA.Drugsthatinhibit
DNA methyltransferases and thus cause gene demethylation
have also been developed, but improved targeting of these
drugs is needed for practical clinical use.
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